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ABSTRACT
Introduction: Diabetes mellitus and diabetic
nephropathy (DN) are prevalent and costly to manage.
DN is the leading cause of end-stage kidney disease.
Conventional therapy blocking the renin–angiotensin
system has only achieved limited effect in preserving
renal function. Recent observational data show that the
use of Chinese medicine (CM), a major form of
traditional medicine used extensively in Asia, could
reduce the risk of end-stage kidney disease. However,
existing clinical practice guidelines are weakly
evidence-based and the effect of CM remains unclear.
This trial explores the effect of an existing integrative
Chinese–Western medicine protocol for the
management of DN.
Objective: To optimise parameters and assess the
feasibility for a subsequent phase III randomised
controlled trial through preliminary evaluation on the
effect of an adjuvant semi-individualised CM
treatment protocol on patients with type 2 diabetes
with stages 2–3 chronic kidney disease and
macroalbuminuria.
Methods and analysis: This is an assessor-blind,
add-on, randomised, controlled, parallel, multicentre,
open-label pilot pragmatic clinical trial. 148 patients
diagnosed with DN will be recruited and randomised
1:1 to a 48-week additional semi-individualised CM
treatment programme or standard medical care.
Primary end points are the changes in estimated
glomerular filtration rate and spot urine albumin-to-
creatinine ratio between baseline and treatment end
point. Secondary end points include fasting blood
glucose, glycated haemoglobin, brain natriuretic
peptide, fasting insulin, C peptide, fibroblast growth
factor 23, urinary monocyte chemotactic protein-1,
cystatin C, nephrin, transforming growth factor-β1
and vascular endothelial growth factor. Adverse
events are monitored through self-completed
questionnaire and clinical visits. Outcomes will be
analysed by regression models. Enrolment started in
July 2015.
Ethics and registration: This protocol is approved
by the Institutional Review Board of the University of
Hong Kong/Hospital Authority Hong Kong West
Cluster (reference number UW 14-301).
Trial registration number : NCT02488252.
INTRODUCTION
The epidemic of diabetes mellitus (DM) is
predicted to rise steadily in incidence and
prevalence all over the world, driven by the
effects of an ageing population and rising
levels of obesity.1 2 It is estimated that 387
million people were having DM in 2014;3
and by 2030, the DM population is projected
to reach 439 million.4 Diabetic nephropathy
Strengths and limitations of this study
▪ This study is the first to assess the potential effi-
cacy of an adjuvant Chinese medicine pro-
gramme in diabetic kidney disease.
▪ Chinese medicine is being extensively used in
Asia and getting popular worldwide. Previous
epidemiological data suggest that Chinese medi-
cine may retard the deterioration of renal func-
tion among patients with diabetic kidney disease.
Hence, it is timely to perform a clinical trial.
▪ This study is a pilot study and the sample size is
not powered to achieve statistical significance.
▪ Since the trial is open-label, subjective outcomes
including quality of life could not be assessed.
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(DN) is the leading cause of end-stage kidney disease
(ESKD)5 and is developed among one-third of all
patients with diabetes.5 6 In Hong Kong, the incidence
of ESKD primarily caused by DN requiring renal
replacement therapy in the form of chronic dialysis or
kidney transplantation doubled from 1996 (26.2%) to
2013 (49.6%).7 Patients with DN have the lowest
adjusted 5-year survival probability of 50.6% when com-
pared with patients with incident renal replacement
therapy with other causes including hypertension
(61.1%) and glomerulonephritis (71.1%).8 DN imposes
a major burden on patients and healthcare systems in
many developed regions.5
The pathogenesis of DN is diverse9–13 and yet to be
fully understood. It involves glycotoxicity, advanced gly-
cation end products and reactive oxygen species which
induce haemodynamic changes and inﬂammation.
Biopsy from patients with DN shows that podocyte loss,
basement membrane thickening, interstitial ﬁbrosis and
tubular atrophy and DN are characterised by proteinuria
clinically. Conventional therapy from the western litera-
ture pinpointing a few selected pathways, such as the
widely advocated blockade of the renin–angiotensin
system, has only achieved modest efﬁcacy in treating DN.6
Combined therapy with several conventional regimes, for
instance, ACE inhibitor and angiotensin receptor blocker
may not be as efﬁcacious as believed.6 14 No speciﬁc ther-
apies for DN or renal ﬁbrosis are available currently.
Chinese medicine (CM) is a popular complementary
remedy in addition to standard medical care among the
Chinese in Hong Kong.15 16 A recent observational study
in Taiwan shows that the use of CM is associated with an
average risk reduction of 59% of ESKD when compared
with non-users in a 6-year period. However, the risk reduc-
tion varies signiﬁcantly across different subgroups of
patients stratiﬁed clinically based on CM theory.17 Despite
its popularity, there is no evidence-based clinical guide-
line for CM as an adjuvant therapy to standard medical
care in managing DN.
An integrative Chinese–Western medicine clinical
management protocol for DN was developed by reviews
of existing clinical management guidelines and an
expert consensus from CM nephrologists in mainland
China in 2012.18 The adjuvant CM treatment consists of
ﬁve different CM formulas corresponding to ﬁve subgroups
of patients stratiﬁed by clinical manifestations. A prelimin-
ary evaluation on renal clinical outcomes among patients
with DN attending an ongoing local CM service pro-
gramme based on the captioned protocol shows stabilised
glomerular ﬁltration rate (GFR), reduced albuminuria and
reduced glycated haemoglobin (HbA1c) level. Recent evi-
dence from in vitro and in vivo studies suggested that the
effect of these herbal medicines in reducing proteinuria
and alleviating decline of renal function could be asso-
ciated with attenuated podocyte apoptosis and detach-
ment,19–21 reduced oxidative stress21 22 and suppressed
transforming growth factor-β (TGF-β) production,23 24
through some of the important pathways including TGF-β/
Smad,23 24 mitogen-activated protein kinase/extracellular
signal-regulated kinase (MAPK/ERK)25 and nuclear factor
kappa B (NF-κB)26 signalling pathway. In this pilot study,
we aim to explore the effect of the captioned protocol on
renal outcomes when used as an add-on therapy for
patients with DN in the existing healthcare setting.
OBJECTIVE
To optimise parameters and access the feasibility for a
subsequent phase III randomised controlled trial (RCT)
through preliminary evaluation on the effect of the adju-
vant semi-individualised CM treatment protocol on
patients with type 2 diabetes with stages 2–3 chronic
kidney disease (CKD) and macroalbuminuria.
METHOD/DESIGN
Study design
This is an assessor-blind, add-on, randomised, con-
trolled, parallel, multicentre, open-label pragmatic clini-
cal trial. The ﬂow of study is summarised in ﬁgure 1.
Figure 1 Flow of study.
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Inclusion and exclusion criteria
Patients: (1) diagnosed with type 2 diabetes for at least
5 years; (2) with an estimated GFR≥30<90 mL/min/
1.73 m2 conﬁrmed with repeat testing over 3 or more
months calculated by the abbreviated Modiﬁcation of
Diet in Renal Disease (MDRD) study equation;27 (3)
persistent macroalbuminuria with spot urine albumin-
to-creatinine ratio (UACR) ≥300 mg/g conﬁrmed by at
least two consecutive ﬁrst morning void urine samples;
(4) aged between 35 and 80 years; (5) on a stable dose
of antidiabetic drug including insulin for 12 weeks and
(6) on a stable dose of ACE inhibitor or angiotensin
receptor blocker for 12 weeks will be recruited.
Patients: (1) with a known history of glomeruloneph-
ritis, polycystic kidney disease, systemic lupus erythema-
tosus or any suggestive evidence of non-diabetic
glomerulopathy; (2) with a known history of kidney
transplant; (3) with concurrent severe disorders of the
heart, brain, liver and haematopoietic system, tumour,
mental disorder; (4) deranged liver function; (5) with
poorly controlled blood pressure; (6) with a known
history of intolerance or malabsorption of oral medica-
tions; (7) uncontrollable urinary infection; (8) experien-
cing pregnancy and (9) participating in other clinical
trials within 30 days will be excluded.
Sample size calculation
Currently, there is no consensus on the sample size cal-
culation for pilot studies. Previous studies suggested a
sample size of 12–30 per arm.28–31 Since the primary
objective of this trial is to explore the feasibility of a sub-
sequent main study and have a preliminary evaluation
on the effect of CM on patients with DN, the sample
size calculation is based on control of the inﬂation
factor (IF) to the estimation of sample size for the subse-
quent main study.31
The standard deviation used for sample size calculation
for the main study could be underestimated by a pilot
study and should be adjusted by an IF.31 IF is calculated
based on the size of the pilot study and the conﬁdence
level of achieving at least the desired power in the main
study. The actual achieved power of the main study
depends on the nominal power set for the main study
and the IF.
In order to be 95% conﬁdent (two-sided) that the sub-
sequent main study actually achieves a power of 80%
with nominal power set at 90% (ie, a 10% power
forfeit), the IF should be <1.15. At IF=1.15, a sample size
of 80 is therefore needed to have 95% one-sided conﬁ-
dence that the main study will achieve at least the
nominal power to test the hypothesis that an add-on of
the whole CM treatment programme could be more
effective in stabilising the GFR among patients with DN
when compared with having standard care alone. For
subgroup analysis, a sample size of 25 patients per sub-
group could achieve 80% one-sided conﬁdence that the
effect of stabilising GFR is different within subgroups of
similar CM clinical pattern.
With ﬁve subgroups, a sample size of 148 patients is
needed in this pilot trial to allow a 15% attrition rate.
Recruitment and setting
Patients are recruited from Queen Mary Hospital
Specialist Renal Outpatients Clinic, Sai Ying Pun Family
Medicine Specialty Clinic, Sai Ying Pun Jockey Club
General Out-patient Clinic, Kennedy Town Jockey Club
General Out-patient Clinic, Aberdeen Family Medicine
Specialty Clinic, Aberdeen Jockey Club General
Out-patient Clinic; and Diabetes Complication
Screening Clinic and Renal Clinic of Tung Wah
Hospital. Patients diagnosed with diabetes and CKD
stage 2–3 with macroalbuminuria are referred to the
principal investigator (PI), co-investigator (Co-I), or
Chinese medicine practitioner (CMP) for further assess-
ment. The aim, procedures, nature of study, possible
side effects of the CM treatment programme and right
of unconditional withdrawal are explained by PI or Co-I
before written consent is obtained from each patient
who agrees to take part in the study.
All patients will undergo a 2-week run-in period,
during which they are asked to keep their medication
dosage ﬁxed. A blood sample will be taken and tested to
check liver function (γ-glutamyltransferase, alanine
transaminase (ALT), alkaline phosphatase, total protein,
aspartate transaminase (AST), bilirubin, albumin) and
renal function (sodium, chloride, urea, potassium, cre-
atinine) in the Department of Pathology & Clinical
Biochemistry of Queen Mary Hospital or local clinical
laboratories of other hospitals. Patients are considered
eligible for the study if their liver functions are normal.
A random sequence is generated by and encrypted
with computer by an independent research assistant
(RA). Sealed opaque envelopes containing an allocation
sequence are sent to the outpatient clinics. The pass-
word of the sequence is kept in a sealed, duly-signed
opaque envelope locked by RA and Co-I. The alloca-
tion sequence is concealed from PI and Co-Is respon-
sible for patient screening, recruitment and assignment
of CM subgroup stratiﬁcation. Eligible candidates are
randomised to either the active treatment arm or
control arm. The allocation will be explained by the
CMP I or II to the patient. The allocation will be
masked from the outcome assessor. The participant
could not be masked due to the nature of treatment.
Since the clinical outcomes under investigation are
objective, placebo effect should be minimised. The dis-
tribution of known and unknown confounding factors
among the intervention group and control group is
balanced by the randomisation.
Intervention and control
The intervention under investigation is a semi-
individualised CM treatment protocol used on top of
standard medical care. The programme consists of ﬁve
different CM herbal formulations corresponding to ﬁve
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different subgroups of patients stratiﬁed by clinical man-
ifestations according to classical CM theory:
A, for the subgroup of ‘spleen and kidney Qi
deﬁciency’:
Radix Aucklandiae (Mu Xiang), Rhizoma Pinelliae
Praeparatum (Fa Ban Xia), Rhizoma Atractylodis
Macrocephalae (Bai Zhu), Poria (Fu Ling), Radix et
Rhizoma Glycyrrhizae Praeparata cum Melle (Zhi Gan
Cao), Fructus Amomi (Sha Ren), Pericarpium citri reticu-
latae (Chen Pi), Radix et Rhizoma Ginseng (Ren Shen),
Radix Rehmanniae Praeparata (Shu Di Huang), Fructus
Corni (Shan Zhu Yu), Rhizoma Dioscoreae (Shan Yao),
Cortex Moutan (Mu Dan Pi), Rhizoma Alismatis (Ze Xie).
B, for the subgroup of ‘spleen and kidney Yang
deﬁciency’:
Rhizoma Atractylodis Macrocephalae (Bai Zhu),
Fructus Chaenomelis (Mu Gua), Radix Aucklandiae
(Mu Xiang), Fructus Tsaoko (Cao Guo), Semen Arecae
(Bing Lang), Radix Aconti Lateralis Praeparata (Hei
Shun Pian), Poria (Fu Ling), Rhizoma Zingiberis (Gan
Jiang), Radix et Rhizoma Glycyrrhizae Praeparata cum
Melle (Zhi Gan Cao), Rhizoma Zingiberis Recens
(Sheng Jiang), Fructus Jujubae (Da Zao), Radix
Rehmanniae Praeparata (Shu Di Huang), Fructus Corni
(Shan Zhu Yu), Rhizoma Dioscoreae (Shan Yao), Cortex
Moutan (Mu Dan Pi), Rhizoma Alismatis (Ze Xie),
Ramulus Cinnamomi (Gui Zhi).
C, for the subgroup of ‘spleen and kidney Qi and Ying
deﬁciency’:
Radix et Rhizoma Ginseng (Ren Shen), Radix
Astragali (Huang Qi), Radix Rehmanniae Praeparata
(Shu Di Huang), Fructus Corni (Shan Zhu Yu),
Rhizoma Dioscoreae (Shan Yao), Poria (Fu Ling),
Cortex Moutan (Mu Dan Pi), Rhizoma Zingiberis
Recens (Sheng Jiang), Fructus Jujubae (Da Zao).
D, for the subgroup of ‘liver and kidney Ying
deﬁciency’:
Radix Rehmanniae Praeparata (Shu Di Huang),
Fructus Corni (Shan Zhu Yu), Rhizoma Dioscoreae
(Shan Yao), Poria (Fu Ling), Cortex Moutan (Mu Dan
Pi), Rhizoma Alismatis (Ze Xie), Fructus Ligustri Lucidi
(Nv Zhen Zi), Herba Ecliptae (Mo Han Lian).
E, for the subgroup of ‘Ying and Yang deﬁciency’:
Radix Rehmanniae Praeparata (Shu Di Huang),
Fructus Corni (Shan Zhu Yu), Rhizoma Dioscoreae
(Shan Yao), Poria (Fu Ling), Cortex Moutan (Mu Dan
Pi), Rhizoma Alismatis (Ze Xie), Ramulus Cinnamomi
(Gui Zhi), Radix Aconti Lateralis Praeparata (Hei Shun
Pian), Fructus Ligustri Lucidi (Nv Zhen Zi), Herba
Ecliptae (Mo Han Lian).
Patients with diabetic kidney disease provided consent
are further assessed by the CMP and categorised into
one of the ﬁve different CM subgroups based on the
Guiding Principle of Clinical Research on New Drugs of
Chinese Medicine.32 The CM diagnoses are based on
clinical manifestation as follows:
A, for the subgroup of ‘spleen and kidney Qi
deﬁciency’:
Primary manifestation: fatigue, shortness of breath,
torpid intake, lumbago.
B, for the subgroup of ‘spleen and kidney Yang
deﬁciency’:
Primary manifestation: fear of cold, fatigue, shortness
of breath, torpid intake, lumbago.
C, for the subgroup of ‘spleen and kidney Qi and Ying
deﬁciency’:
Primary manifestation: fatigue, lumbago, dry mouth,
heat vexation.
D, for the subgroup of ‘liver and kidney Ying deﬁciency’:
Primary manifestation: dizziness or headache,
lumbago, dry mouth, heat vexation.
E, for the subgroup of ‘Ying and Yang deﬁciency’:
Primary manifestation: fear of cold, lumbago, dry
mouth, heat vexation.
Patients with at least one episode of all the primary
manifestations of each CM subgroup listed above during
the 2 weeks before consultation are considered eligible
for the corresponding group. To enhance the speciﬁcity
of categorisation, patients having multiple manifestations
that ﬁt more than one subgroup are excluded.
The treatment programme is originated from an exist-
ing clinical practice guideline being used in mainland
China derived from expert consensus.18 Patients rando-
mised to the intervention arm will receive the corre-
sponding formulations on top of standard medication,
as stated above. Minor adjustment of the herbs is
allowed based on an individual’s condition and deter-
mined by the CMP to reﬂect actual clinical practice. All
patients continue their standard medications and follow-
ups. Patients randomised to the control group will
receive consultation from the CMP at baseline, study
midpoint (week 24) and study end point (week 48) in
addition to standard care. Patients will have 5 days of
medicine per week and are advised to take the medica-
tion twice per day dissolved in boiling water in the ﬁrst
5 days of the week.
Herbal safety
Herbal medicines with known toxicity that are listed in
Schedule 1, Chapter 549, Chinese Herbal Medicines,
Chinese Medicine Ordinance of Hong Kong are
excluded. Soluble herbal granules prepared by
PuraPharm are used in this study. The production
process is in strict compliance with standards of Good
Manufacturing Practice (GMP). The CM is prescribed
and dispensed through the clinics of the School of
Chinese Medicine, Li Ka Shing Faculty of Medicine or
Clinical Trial Pharmacy of Queen Mary Hospital comply-
ing with the standard of practice of pharmacy. A fully
registered CMP is responsible for clinical diagnosis and
prescription. At week 6, patients will undergo liver func-
tion tests and brain natriuretic peptide (BNP) test for
monitoring of liver toxicity and cardiotoxicity. To further
ensure patient safety, we only recruit patients with stages
2–3 CKD who are more clinically stable to participate in
the study.
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Outcome measurement
The primary outcome measures are the changes in the
estimated GFR and spot UACR between the baseline
(week 0) and treatment end point (week 48). Secondary
measures include changes from baseline (week 0) to
end of treatment (week 48) in fasting blood glucose
(FBG), HbA1c, serum BNP, fasting serum insulin,
serum C peptide, serum ﬁbroblast growth factor 23
(FGF23), urinary monocyte chemotactic protein-1
(MCP-1), urinary cystatin C, urinary nephrin, urinary
TGF-β1 and urinary vascular endothelial growth factor
(VEGF). A self-complete questionnaire is distributed to
the participants to monitor occurrence of adverse
events, and they are advised to inform the PI or RA
immediately.
Estimated GFR, UACR, FBG, HbA1c and liver function
test are ordered by the Renal Clinic and assessed by the
Division of Clinical Biochemistry, Queen Mary Hospital
or local clinical laboratories of other hospitals which are
accredited by the College of American Pathologists.
BNP, insulin, C peptide, FGF23, MCP-1, cystatin C,
nephrine, TGF-β1 and VEGF assessment will be per-
formed at PI’s research laboratory by an independent
RA. Estimated GFR is calculated using the abbreviated 4-
variable MDRD study equation with serum creatinine,
age, ethnicity and gender. Clinical presentations and
CM syndromic diagnosis will be assessed in a structured
consultation developed for this purpose. To ensure
consistency and reliability of assessment and minimise
bias from investigators across the study, patients will be
assessed by the same CMP during each visit based on
standard CM practice. Follow-up consultations are held
for all patients weekly in the ﬁrst month and monthly
subsequently. Evaluation of outcomes will be per-
formed at weeks 24 (on treatment) and 48 (end of
treatment). The follow-up schedule is summarised
below in table 1.
The baseline demographics including age, sex, body
mass index, duration of diabetes, duration of diagnosed
diabetic kidney disease and concurrent medications
used are collected through the clinical management
system of the Specialist Renal Outpatient Clinic. Patient
ﬂow measured as enrolled case per month and follow-up
rate are recorded for the consideration of subsequent
RCT design.
Handling of withdrawal and dropout
In order to maximise participants’ compliance, ﬁrst, we
have a thorough consent process for all participants with
details of the study schedule, potential side effects of
treatment, and the responsibilities of the participants
explained. Second, we scrutinise potential participants
carefully during a 2-week run-in period in order to
exclude ineligible and low compliance participants
before randomisation. Third, an independent email
account and a direct telephone line associated with this
clinical trial have been set up to enable active communi-
cation with patients. Moreover, extra visits will be
arranged for patients if necessary. If any patient plans to
withdraw or drop out, the study team will communicate
with the patient to determine and resolve the problem
in order to retain the participant.
Termination criteria
The trial will be terminated for a speciﬁc participant if
she or he has: (1) presence of serious adverse effect(s)
in the interventional group; (2) hypersensitivity towards
Chinese herbal medicine and (3) participation in
another clinical trial. The whole study will be terminated
under the following circumstances: (1) presence of
serious adverse effect(s) related to Chinese herbal medi-
cine with supportive evidence and (2) completion of all
follow-up assessments.
Serious adverse events include adverse events that
result in death, require either hospitalisation or the pro-
longation of hospitalisation, are life-threatening, result
in a persistent or signiﬁcant disability/incapacity or
result in a congenital anomaly/birth defect. Other
important medical events, based on appropriate medical
judgement, may also be considered serious adverse
events if a patient’s health is at risk and intervention is
required to prevent an outcome mentioned.
Table 1 Follow-up schedule
Enrolment Postallocation—treatment period
Before treatment
(up to 30 days prior
to baseline)
Allocation
Week 0,
day 1
Weeks 1–4
(±3 days)
After
6 weeks
(±7 days)
After 24 and
48 weeks
(±7 days)
Screening of eligibility X
Informed consent X
Medical history X
Renal and liver function test X X X
Randomised allocation X
Intervention (for interventional group) X X X X
Standard care (for all patients) X X X X
Outcome assessment (Spot urine+blood) X X
Adverse events X X X X
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Data analysis
Missing values, if any, will be imputed with regression.
The analysis will follow the intention-to-treat approach.
Patients without a postrandomisation assessment for a
particular efﬁcacy end point will be excluded from the
analysis of that end point. SAS and SPSS will be used for
the data analysis.
The demographics of each group will be presented as
means. Sex will be presented as the male:female ratio.
Regression analyses will be used to compare the adjusted
mean of estimated GFR, UACR, HbA1c, FBG, BNP,
insulin, C peptide, FGF23, MCP-1, cystatin C, nephrin,
TGF-β1 and VEGF at week 48 between (1) the combin-
ation of all intervention groups and combination of all
control groups, (2) individual treatment subgroup and its
matching control group and (3) different control groups
with the corresponding baseline values as covariates. Data
will be presented as the difference in adjusted means
between the intervention arm and control arm with a
95% CI and the corresponding p value. A change score
analysis will be performed as supplementary analysis.
The adverse events are recorded based on the
Common Terminology Criteria for Adverse Events V.4.03
and will be analysed in a narrative manner. The adverse
events are categorised into ﬁve grades: grade (1) mild;
asymptomatic or mild symptoms; clinical or diagnostic
observations only; no intervention indicated; grade (2)
moderate; minimal, local or non-invasive intervention
indicated; limiting age-appropriate instrumental activi-
ties of daily living; grade (3) severe or medically signiﬁ-
cant but not immediately life-threatening; hospitalisation
or prolongation of hospitalisation indicated; disabling;
limiting self-care activities of daily living; grade (4) life-
threatening consequences; urgent intervention indi-
cated; and grade (5) death related to adverse events.
The percentage of all adverse events and the rate of
attrition due to adverse events will be compared
between intervention groups and control groups.
To minimise type I error inﬂation, the analysis will
follow a hierarchical approach in the order of (1) indi-
vidual treatment subgroup versus its control subgroup
and (2) combination of all intervention groups versus
the combination of all control groups as to avoid type I
error inﬂation. The primary outcomes are the change of
GFR and UACR.
Subgroup analysis will be performed for CKD stages 2
and 3 separately. Sensitivity analyses will be performed
for (1) missing data imputed with regression, (2) missing
data imputed with last-observation-carried-forward
(LOCF) and (3) per protocol dropout of patients.
Adverse events will be analysed case-by-case and pre-
sented descriptively.
Data management
A trial management committee is formed by the study
team members. Co-Is and RA collect, clean and send
the study data to the committee on a weekly basis. All
data are double-entered to computer and cleaned
before analysis to prevent data entry errors. All data
transfer is encrypted to protect patients’ conﬁdentiality.
The committee holds meetings monthly with experts to
discuss the progress of the trial.
ETHICS CONSIDERATION
This trial is ethically justiﬁed as there are uncertainties
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sus but with no further validation of clinical evidence.
Since the treatment is being used in mainland China
and has the potential to be broadly used in Hong Kong
and beneﬁt local citizens, we believe this trial is worth-
while. All protocol amendments will be approved by the
Institutional Review Board prior to execution.
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